Cargando…

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

INTRODUCTION: Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer. Here, we report a case of abiraterone acetate withdrawal syndrome with transient prostate‐specific antigen de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tani, Masaru, Hayashi, Yujiro, Miki, Airi, Wakita, Teppei, Horibe, Yuki, Kakuta, Yoichi, Tsutahara, Koichi, Takao, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475332/ https://www.ncbi.nlm.nih.gov/pubmed/37667762 http://dx.doi.org/10.1002/iju5.12604

Ejemplares similares

A case of robot‐assisted laparoscopic partial nephrectomy during pregnancy
por: Tsutsui, Kenji, et al.
Publicado: (2023)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
por: Gauthier, Hélène, et al.
Publicado: (2012)

Abiraterone Acetate
Publicado: (2012)

Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study
por: Okamoto, Teppei, et al.
Publicado: (2021)

A case of hypogonadtropic hypogonadism due to hypophysitis discovered by secondary male infertility
por: Konishi, Masatoshi, et al.
Publicado: (2022)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

Abiraterone-Induced Endocrinopathies
por: Decamps, Scarlett, et al.
Publicado: (2023)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Abiraterone: moving up in line?
por: Strijbos, Michiel
Publicado: (2018)

Useful predictors of progression‐free survival for Japanese patients with LATITUDE‐high‐risk metastatic castration‐sensitive prostate cancer who received upfront abiraterone acetate
por: Takahara, Kiyoshi, et al.
Publicado: (2021)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
por: Acharya, M., et al.
Publicado: (2012)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2014)

Prognostic factors for patients treated with abiraterone
por: Alvim, Cecília M, et al.
Publicado: (2019)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
por: James, Aloysius, et al.
Publicado: (2018)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
por: Castellan, Pietro, et al.
Publicado: (2018)

Abiraterone Acetate Complexes with Biometals: Synthesis, Characterization in Solid and Solution, and the Nature of Chemical Bonding
por: Buikin, Petr, et al.
Publicado: (2023)

Fatal fulminant hepatitis in a patient taking abiraterone acetate: a case report
por: Akpokavie, Dela, et al.
Publicado: (2023)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)
por: O'Shaughnessy, J., et al.
Publicado: (2016)

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
por: Poon, Darren M. C., et al.
Publicado: (2016)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
por: Rauch, Simon, et al.
Publicado: (2016)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
por: Katsui, Masahiro, et al.
Publicado: (2018)

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor
por: Hu, Zengchun, et al.
Publicado: (2021)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein
por: Kim, Jinsoo, et al.
Publicado: (2022)

Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies
por: Braeckmans, Marlies, et al.
Publicado: (2022)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2017)

Quadriplegia secondary to abiraterone-induced severe hypokalemia
por: Rajvanshi, Jignesh B., et al.
Publicado: (2019)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Abiraterone-Induced Hypokalemia: A Case Report
por: Nkwocha, Bernard I, et al.
Publicado: (2023)

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
por: Tolcher, A. W., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_roq5lebu9q0l1s3hb6p3423hac